A new CRISPR startup is betting regulators will ease up on gene-editing
“I went to Fyodor and said, ‘Hey, we’re getting all these great results in the clinic with CRISPR, but why hasn’t it scaled?” says Hu. Part of the reason is that most gene-editing companies are chasing the same few conditions, such as sickle-cell, where (as luck would have it) a single edit works for all […]